- Recommendation ID
- NICE considered that if enzalutamide is used in routine clinical practice for treating hormone relapsed metastatic prostate cancer that has been previously treated with abiraterone, data should be collected on resource use and overall survival.
- Any explanatory notes
- The use of enzalutamide for treating metastatic hormone-relapsed prostate cancer previously treated with abiraterone is not covered by this guidance.
Source guidance details
- Comes from guidance
- Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen
- Date issued
- July 2014
|Is this a recommendation for the use of a technology only in the context of research?||N/A|
|Is it a recommendation that suggests collection of data or the establishment of a register?||N/A|